Development Pipeline For more than 29 years, Genentech has excelled at transforming scientific discoveries into breakthrough therapies for patients. Since the start, we have directed our drug discovery efforts toward therapies that would address unmet medical needs. Today, Genentech's development pipeline focuses on oncology, immunology, vascular medicine and specialty therapeutics. The pipeline has both breadth and depth, with more than 30 projects targeting a range of disease areas across all phases of clinical development. The pipeline below is current as of February 22, 2005.

Awaiting FDA Action
Specialty	Nutropin® & Nutropin AQ®	Idiopathic Short Stature
Phase III
Oncology	Avastin™	Adjuvant Colorectal Cancer First-Line Ovarian Cancer* Metastatic Breast Cancer Non-Small Cell Lung Cancer Pancreatic Cancer Renal Cell Carcinoma
	Herceptin®	Adjuvant Breast Cancer First-Line Metastatic Breast Cancer in Combination with Taxotere**
	Rituxan®	Front-Line Aggressive Non-Hodgkin's Lymphoma** Front-Line Indolent Non-Hodgkin's Lymphoma** Indolent Non-Hodgkin's Lymphoma Maintenance** Relapsed Chronic Lymphocytic Leukemia
	Tarceva™	Pancreatic Cancer
Immunology	Rituxan®	ANCA-Associated Vasculitis Lupus Nephritis* Moderate-to-Severe Rheumatoid Arthritis* Primary Progressive Multiple Sclerosis Refractory Rheumatoid Arthritis Systemic Lupus Erythematosus*
	Xolair®	Pediatric Asthma
Vascular	Lucentis™	Wet Form of Age-Related Macular Degeneration
Phase II
Oncology	Avastin™	Refractory Ovarian Cancer
	Avastin™ + Tarceva™	Non-Small Cell Lung Cancer Renal Cell Carcinoma
	Omnitarg™	Breast Cancer Lung Cancer Ovarian Cancer
Immunology	Humanized Anti-CD20	Rheumatoid Arthritis
	Rituxan®	Relapsed Remitting Multiple Sclerosis
	Xolair®	Peanut Allergy
Vascular	Topical VEGF	Diabetic Foot Ulcers*
Pre-IND/Phase I
Oncology	Apo2L/TRAIL	Cancer Therapy
	Topical Hedgehog Antagonist	Basal Cell Carcinoma*
Immunology	BR3-Fc	Rheumatoid Arthritis*
Specialty	Anti-NGF	Acute and Chronic Pain

* Preparing for Phase
** Preparing for FDA Filing